Oral norovirus vaccine clinical trials to begin

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced Tuesday the initiation of a Phase 1 clinical trial of the first oral norovirus tablet vaccine. "The start of the norovirus Phase 1 study is another important milestone for Vaxart's oral vaccine platform," said Wouter Latour, ["]